Takeda Pharmaceutical Company has teamed up with Charles River to deliver preclinical candidates across its four core therapeutic areas.

Under the multi-year drug discovery collaboration, the two companies will work on multiple integrated programmes for oncology, gastroenterology, neuroscience and rare disease therapeutic areas.

As agreed, Takeda will pay Charles River a one-time, upfront fee for the partnership. Charles River will also receive additional development payments that can value more than $50m per programme upon reaching preclinical and clinical milestones for candidates.

Furthermore, the agreement includes the provision of potential commercial milestone payments of up to $120m and royalties on launched drug products.

Charles River chairman, president and CEO James C. Foster said: “We are pleased to expand our relationship with Takeda, who shares our commitment to bring innovative, safe, and effective medicines to patients as quickly and efficiently as possible.

“We expect the expertise of Charles River and Takeda will prove to be a powerful combination in delivering novel drug candidates.”

Under the collaboration, Takeda will leverage Charles River’s drug discovery expertise to support the development of drug candidates.

It will also use Charles River’s drug discovery and safety assessment platform to study therapeutic approaches and advance the programmes towards candidate status.

Subsequently, Takeda may choose to pursue clinical development of the candidates.

Takeda global head of Research Steve Hitchcock said: “Takeda has a long history of working with Charles River across our drug discovery and development portfolio and are confident in their breadth of experience and commitment to excellent science.

“Leveraging Charles River’s integrated discovery capabilities is a natural extension of our relationship.”